Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis
Nicholas A. Vitanza(Seattle Children's Hospital), Julie R. Park(Seattle Children's Hospital), Michael C. Jensen(Seattle Children's Hospital), Cindy A. Chang(Seattle Children's Hospital), Annette Künkele(Humboldt-Universität zu Berlin), Rimas J. Orentas(Capital Caring), Ashley Wilson(Center for Infectious Disease Research), Jason K. Yokoyama(Seattle Children's Hospital), Catherine M. Albert(Seattle Children's Hospital), Stephanie Rawlings-Rhea(Seattle Children's Hospital), Christopher Brown, Wenjun Huang(Lishui Central Hospital), Jason N. Wright(Seattle Children's Hospital), Jeffrey G. Ojemann(Seattle Children's Hospital), Rebecca Gardner(Seattle Children's Hospital), Navin Pinto(Seattle Children's Hospital), Kristy Seidel(Fred Hutch Cancer Center), Michael Baldwin(Seattle Children's Hospital), Laura S. Finn(Seattle Children's Hospital), Adam Johnson(Sana Biotechnology (United States)), Juliane Gust(University of Washington)
Cited by 319
Related Papers
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
|New England Journal of Medicine|2016|1.8k
Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults
|Blood|2017|1.1k
Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma
|Clinical Cancer Research|2015|754